source
- GSK partners with Engitix on multi-target liver researchGSK announced a collaboration with London-based Engitix to explore multiple targets for liver disease. Engitix will apply its extracellular matrix-based disease models to uncover new therapeutic op…
- Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisitionNovo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…